Marissa B. Serafin, Angelita Bottega, Taciéli F. da Rosa, Catrine S. Machado, Vitória S. Foletto, Silvana S. Coelho, Augusto D. da Mota & Rosmari Hörner. (2021) Drug Repositioning in Oncology. American Journal of Therapeutics 28:1, pages e111-e117.
Crossref

Lianwei Wang, Dengyang Fang, Jinming Xu & Runlan Luo. (2020) Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review. BMC Cancer 20:1.
Crossref

Gianfranco Natale & Guido Bocci. (2018) Does metronomic chemotherapy induce tumor angiogenic dormancy? A review of available preclinical and clinical data. Cancer Letters 432, pages 28-37.
Crossref

Emilio Rubén Pego, Isaac Fernández & María Jesús Núñez. (2018) Molecular basis of the effect of MMP-9 on the prostate bone metastasis: A review. Urologic Oncology: Seminars and Original Investigations 36:6, pages 272-282.
Crossref

Daniela Vanacore, Mariarosaria Boccellino, Sabrina Rossetti, Carla Cavaliere, Carmine D’Aniello, Rossella Di Franco, Francesco Jacopo Romano, Micaela Montanari, Elvira La Mantia, Raffaele Piscitelli, Flavia Nocerino, Francesca Cappuccio, Giovanni Grimaldi, Alessandro Izzo, Luigi Castaldo, Maria Filomena Pepe, Maria Gabriella Malzone, Gelsomina Iovane, Gianluca Ametrano, Paola Stiuso, Lucio Quagliuolo, Daniela Barberio, Sisto Perdonà, Paolo Muto, Maurizio Montella, Piera Maiolino, Bianca Maria Veneziani, Gerardo Botti, Michele Caraglia & Gaetano Facchini. (2017) Micrornas in prostate cancer: an overview. Oncotarget 8:30, pages 50240-50251.
Crossref

Giuseppina Comito, Coral Pons Segura, Maria Letizia Taddei, Michele Lanciotti, Sergio Serni, Andrea Morandi, Paola Chiarugi & Elisa Giannoni. (2016) Zoledronic acid impairs stromal reactivity by inhibiting M2-macrophages polarization and prostate cancer-associated fibroblasts. Oncotarget 8:1, pages 118-132.
Crossref

Chiara Della Pepa, Carla Cavaliere, Sabrina Rossetti, Marilena Di Napoli, Sabrina C. Cecere, Anna Crispo, Carlo De Sangro, Emanuela Rossi, Dino Turitto, Domenico Germano, Gelsomina Iovane, Massimiliano Berretta, Carmine D’Aniello, Salvatore Pisconti, Luigi Maiorino, Bruno Daniele, Cesare Gridelli, Sandro Pignata & Gaetano Facchini. (2017) Predictive Comprehensive Geriatric Assessment in elderly prostate cancer patients. Anti-Cancer Drugs 28:1, pages 104-109.
Crossref

Gaetano Facchini, Orazio Caffo, Cinzia Ortega, Carmine D'Aniello, Marilena Di Napoli, Sabrina C. Cecere, Chiara Della Pepa, Anna Crispo, Francesca Maines, Fiorella Ruatta, Gelsomina Iovane, Salvatore Pisconti, Maurizio Montella, Massimiliano Berretta, Sandro Pignata & Carla Cavaliere. (2016) Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival. Frontiers in Pharmacology 7.
Crossref

Konstantinos E. Papathanasiou & Konstantinos D. Demadis. 2015. Handbook of Polymers for Pharmaceutical Technologies. Handbook of Polymers for Pharmaceutical Technologies 89 124 .

KE-WANG LUO, GRACE GAR-LEE YUE, CHUN-HAY KO, SI GAO, JULIA KIN-MING LEE, GANG LI, KWOK-PUI FUNG, PING-CHUNG LEUNG & CLARA BIK-SAN LAU. (2015) The combined use of Camellia sinensis and metronomic zoledronate in 4T1 mouse carcinoma against tumor growth and metastasis. Oncology Reports 34:1, pages 477-487.
Crossref

Ke-Wang Luo, Chun-Hay Ko, Grace Gar-Lee Yue, Si Gao, Julia Kin-Ming Lee, Gang Li, Kwok-Pui Fung, Ping-Chung Leung, Andreas Evdokiou & Clara Bik-San Lau. (2014) The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model. Journal of Cancer Research and Clinical Oncology 141:6, pages 1025-1036.
Crossref

S. Ishtiaq, S. Edwards, A. Sankaralingam, B.A.J. Evans, C. Elford, M.L. Frost, I. Fogelman & G. Hampson. (2015) The effect of nitrogen containing bisphosphonates, zoledronate and alendronate, on the production of pro-angiogenic factors by osteoblastic cells. Cytokine 71:2, pages 154-160.
Crossref

Guohua Huang, Yin Lu, Changhong Lu, Mingyue Zheng & Yu-Dong Cai. (2015) Prediction of Drug Indications Based on Chemical Interactions and Chemical Similarities. BioMed Research International 2015, pages 1-14.
Crossref

Annabelle Chow, Amy Wong, Giulio Francia, Shan Man, Robert S. Kerbel & Urban Emmenegger. (2013) Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy. Investigational New Drugs 32:1, pages 47-59.
Crossref

Ke-Wang Luo, Chun-Hay Ko, Grace G.L. Yue, Michelle Y.Y. Lee, Wing-Sum Siu, Julia K.M. Lee, Wai-Ting Shum, Kwok-Pui Fung, Ping-Chung Leung, Gang Li, Andreas Evdokiou & Clara B.S. Lau. (2013) Anti-tumor and anti-osteolysis effects of the metronomic use of zoledronic acid in primary and metastatic breast cancer mouse models. Cancer Letters 339:1, pages 42-48.
Crossref

Ana Carolina Uchoa Vasconcelos, Soraya de Azambuja Berti-Couto, Maria Antonia Figueiredo, Fernanda Gonçalves Salum, Tiago Giuliani Lopes & Karen Cherubini. (2013) Laboratory methods and biomarkers in the evaluation of bisphosphonate effects on body tissues: a literature review. Journal of Oral Pathology & Medicine 42:8, pages 577-586.
Crossref

Subash C. Gupta, Bokyung Sung, Sahdeo Prasad, Lauren J. Webb & Bharat B. Aggarwal. (2013) Cancer drug discovery by repurposing: teaching new tricks to old dogs. Trends in Pharmacological Sciences 34:9, pages 508-517.
Crossref

M R Milone, B Pucci, F Bruzzese, C Carbone, G Piro, S Costantini, F Capone, A Leone, E Di Gennaro, M Caraglia & A Budillon. (2013) Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells. Cell Death & Disease 4:5, pages e641-e641.
Crossref

Giuseppe Di Lorenzo, Carmine D'Aniello, Carlo Buonerba, Piera Federico, Pasquale Rescigno, Livio Puglia, Matteo Ferro, Davide Bosso, Carla Cavaliere, Giovannella Palmieri, Guru Sonpavde & Sabino De Placido. (2013) Peg-filgrastim and cabazitaxel in prostate cancer patients. Anti-Cancer Drugs 24:1, pages 84-89.
Crossref

Renato Franco, Paolo Chieffi, Sisto Perdonà, Gaetano Facchini & Michele Caraglia. 2013. Prostate Cancer: Shifting from Morphology to Biology. Prostate Cancer: Shifting from Morphology to Biology 87 109 .

Jean-Baptiste Lattouf & Fred Saad. 2013. Prostate Cancer: A Comprehensive Perspective. Prostate Cancer: A Comprehensive Perspective 935 940 .

Catherine A. Sánchez, Alejandro J. Mercado, Héctor R. Contreras, Juan C. Cabezas, Christian C. Huidobro & Enrique A. Castellón. (2012) Pharmacoperone IN3 enhances the apoptotic effect of leuprolide in prostate cancer cells by increasing the gonadotropin-releasing hormone receptor in the cell membrane. Anti-Cancer Drugs 23:9, pages 959-969.
Crossref

Lavinia Insalaco, Francesca Di Gaudio, Marianna Terrasi, Valeria Amodeo, Stefano Caruso, Lidia Rita Corsini, Daniele Fanale, Naomi Margarese, Daniele Santini, Viviana Bazan & Antonio Russo. (2012) Analysis of molecular mechanisms and anti‐tumoural effects of zoledronic acid in breast cancer cells. Journal of Cellular and Molecular Medicine 16:9, pages 2186-2195.
Crossref

H K Koul, S Koul & R B Meacham. (2011) New role for an established drug? Bisphosphonates as potential anticancer agents. Prostate Cancer and Prostatic Diseases 15:2, pages 111-119.
Crossref

Xu-yuan Li, Ying-cheng Lin, Wan-lan Huang, Chao-qun Hong, Jiong-yu Chen, Yan-jie You & Wei-bing Li. (2011) Zoledronic acid inhibits proliferation and impairs migration and invasion through downregulating VEGF and MMPs expression in human nasopharyngeal carcinoma cells. Medical Oncology 29:2, pages 714-720.
Crossref

Matti Aapro & Fred Saad. (2012) Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid. Therapeutic Advances in Urology 4:2, pages 85-101.
Crossref

Francesco Grossi, Filippo de Marinis, Vittorio Gebbia, Ferdinando Riccardi, Orazio Caffo, Teresa Gamucci, Francesco Ferraù, Mario Nardi, Luca Moscetti, Luca Boni, Davide Dondi & Enzo Galligioni. (2011) A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology 69:2, pages 369-375.
Crossref

K Mross & S Steinbild. (2012) Metronomic anti-cancer therapy – an ongoing treatment option for advanced cancer patients. journal of Cancer Therapeutics and Research 1:1, pages 32.
Crossref

Maria Michailidou & Ingunn Holen. 2012. Prevention of Bone Metastases. Prevention of Bone Metastases 145 169 .

Fred Saad & Jean-Baptiste Lattouf. 2012. Prevention of Bone Metastases. Prevention of Bone Metastases 109 126 .

Stephen Metcalf, Hardev S Pandha & Richard Morgan. (2011) Antiangiogenic effects of zoledronate on cancer neovasculature. Future Oncology 7:11, pages 1325-1333.
Crossref

James R. Berenson. (2011) Antitumor effects of bisphosphonates. Current Opinion in Supportive & Palliative Care 5:3, pages 233-240.
Crossref

Joaquim Bosch-Barrera, Sofía D. Merajver, Javier A. Menéndez & Catherine Van Poznak. (2011) Direct antitumour activity of zoledronic acid: preclinical and clinical data. Clinical and Translational Oncology 13:3, pages 148-155.
Crossref

Luis Costa, Peter Harper, Robert E. Coleman & Allan Lipton. (2011) Anticancer evidence for zoledronic acid across the cancer continuum. Critical Reviews in Oncology/Hematology 77, pages S31-S37.
Crossref

Paolo Grieco, Renato Franco, Giuseppina Bozzuto, Laura Toccacieli, Alessandro Sgambato, Monica Marra, Silvia Zappavigna, Mario Migaldi, Giulio Rossi, Stefano Striano, Luigi Marra, Luigi Gallo, Achille Cittadini, Gerardo Botti, Ettore Novellino, Agnese Molinari, Alfredo Budillon & Michele Caraglia. (2011) Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells. Journal of Cellular Biochemistry 112:1, pages 341-353.
Crossref

Ingunn Holen & Robert E Coleman. (2010) Anti-tumour activity of bisphosphonates in preclinical models of breast cancer. Breast Cancer Research 12:6.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Metronomic administration of Zoledronic Acid and Taxotere combination in castration resistant prostate cancer patients: Phase I ZANTE trial

Articles from other publishers (36)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature